Firmagon (degarelix; Ferring/Astellas) Drug Analysis 2018: A Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist that Directly Binds to GnRH Receptors in the Anterior Pituitary Gland - ResearchAndMarkets.com

The "Drug Analysis: Firmagon" drug pipelines has been added to ResearchAndMarkets.com's offering.

Drug Overview

Firmagon (degarelix; Ferring/Astellas) is a gonadotropin-releasing hormone (GnRH) receptor antagonist that directly binds to GnRH receptors in the anterior pituitary gland, rapidly reducing the circulating gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and leading to the rapid suppression of testosterone in men.

This mechanism stands in contrast to GnRH agonists that, over time, downregulate and desensitize GnRH receptors in the pituitary, leading to reduced secretion of LH and downstream testosterone. However, GnRH agonists are also accompanied by a biochemical surge in testosterone known as a flare that typically requires co-administration of antiandrogens to help prevent flare side effects such as spinal cord compression, bone pain, and urethral obstruction.

Key Topics Covered:

Product Profiles

Firmagon: Prostate cancer

List of Figures

Figure 1: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country M, 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8ffkzn/firmagon?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006267/en/